XZB 0003
Alternative Names: XZB-0003Latest Information Update: 31 Mar 2023
Price :
$50 *
At a glance
- Originator Undisclosed Company; Xuanzhu Biopharmaceutical
- Developer Xuanzhu Biopharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 02 Mar 2023 Preclinical trials in Solid tumours in China, prior to March 2023 (Xuanzhu Biopharm pipeline, March 2023)